Preventing Cytomegalovirus Infection in High-Risk Bone Marrow Transplant Patients
Source: Preventing Cytomegalovirus Infection in High-Risk Bone Marrow Transplant Patients

Interactive Virtual Presentation

In this CME-certified interactive presentation, Kathleen Mullane, DO, PharmD, provides expert perspectives on optimal strategies for preventing and managing CMV infection in patients undergoing bone marrow transplantation.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients at high risk for CMV infection post bone marrow transplantation
  • Apply clinical practice guidelines and the results of recent clinical studies to prophylaxis for and treatment of CMV infection in the setting of bone marrow transplantation
  • Evaluate the impact of clinical studies of novel CMV prophylaxis and treatment strategies on current and future care of bone marrow transplantation patients

Topics covered include:

  • CMV Infection and Disease Following Bone Marrow Transplantation
  • Management of CMV Viremia: Prophylaxis
  • Management of CMV Viremia: Preemptive Therapy

CCO Interactive Virtual Presentations contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Faculty

  • Kathleen Mullane
    DO, PharmD

Credit Information

  • Release Date:
    December 13, 2017
  • Expiration Date:
    December 12, 2018
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Kathleen Mullane, DO, PharmD


Professor of Medicine
Division of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Attending Physician
Immunocompromised Host Infectious Diseases Consult Service
University of Chicago Medicine
Chicago, Illinois

Kathleen Mullane, DO, PharmD, has disclosed that she has received consulting fees from Astellas, Chimerix, and Merck; fees for non-CME/CE activities from Astellas and Merck; and funds for research support from Actelion, AiCuris, Ansun, Astellas, Chimerix, Gilead Sciences, Glaxon, MedImmune, Merck, Rebiotix, Sage, Seres, Shire, Summit, and Scynexis.

 

Staff

Ryan P. Topping, PhD


Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

Megan K. Murphy, PhD


Clinical Editor

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.
 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
 

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for hematologic oncologists and other clinicians practicing within BMT centers.


Goal

The goal of this activity is to close the knowledge and practice gaps in managing CMV.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients at high risk for CMV infection post bone marrow transplantation
  • Apply clinical practice guidelines and the results of recent clinical studies to prophylaxis for and treatment of CMV infection in the setting of bone marrow transplantation
  • Evaluate the impact of clinical studies of novel CMV prophylaxis and treatment strategies on current and future care of bone marrow transplantation patients
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Merck & Co., Inc..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 13, 2017, through December 12, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.